Picture supply: Getty Pictures
At first look, shares in shoemaker Dr Martens (LSE: DOCS) might seem to be a cut price. Final 12 months, for instance, the corporate generated fundamental earnings per share of 7p. With the Dr Martens share worth in pennies, which means the price-to-earnings (P/E) ratio is round 12. Not solely that, however these outcomes reported as we speak (30 Could) had been really sharply decrease than the earlier 12 months. If the corporate can get again to its prior 12 months efficiency, the valuation appears even cheaper, with a potential P/E ratio of round 8.
However that may be a huge ‘if’. The outcomes have finished a lot to appease my considerations in regards to the well being of the enterprise. But I don’t see the Dr Martens share worth as a cut price a lot as a attainable worth entice. For now I’ve no plans to take a position.
Iconic enterprise with distinctive model
Let’s begin, although, with some strengths.
Because of its immediately recognisable boot design, coupled with a powerful model, the corporate is ready to cost a premium worth. Although income after tax fell sharply final 12 months, they nonetheless got here in at £69m. With revenues of £877m, which means the enterprise delivered a web revenue margin of seven.8%.
Direct-to-consumer gross sales have been sturdy and grew in low-single-digits final 12 months. Dr Martens has been opening new shops itself and final 12 months elevated its rely of personal outlets by 35. It has centered on bettering its provide chain and as we speak introduced a cost-cutting plan.
Fighting weak client confidence
So why am I nervous about investing within the firm at this level?
Revenues final 12 months declined by 12.3%. I don’t see that as an indication of an organization in strong well being.
The important thing problem was not the retail however the wholesale facet of the enterprise. On one hand, which may not be seen as an issue. Dr Martens has made adjustments in its wholesale technique and says it purposely deliberate to ship decrease volumes into wholesalers in Europe, the Center East and Africa.
However smaller gross sales are hardly ever an indication of a client enterprise performing nicely. I believe on this case they mirror one thing the corporate commented on in its outcomes: difficulties within the US.
That’s Dr Martens’ greatest enterprise. Weak client confidence is hurting spending typically, whereas Dr Martens recognized the boots market as going through “particularly challenging” circumstances.
That bodes poorly. There’s a clear danger that ongoing financial weak spot within the US will have an effect on gross sales this 12 months and maybe past. On high of that, if that financial malaise spreads to different markets, we might see extra income and revenue declines on the shoemaker. The corporate says the present 12 months is “a year of transition”.
Ready for the opposite boot to drop
The underlying enterprise is enticing and the corporate is taking steps to try to benefit from a tricky market.
However falling revenues, falling income, a decrease dividend and better web debt all present the enterprise has its work lower out. The boot market atmosphere makes {that a} harder problem. For now I’ve no plans to take a position.
